Novo Nordisk A/S (NVO) saw its shares decline by 6.3% following the launch of a semaglutide-based weight-loss pill by Hims & Hers Health Inc. (HIMS), a direct competitor to Novo’s flagship drug Wegovy. The new formulation, marketed as Hims Semaglutide 2.4 mg, is priced at $129 per month, significantly below Wegovy’s $1,400 monthly list price.
- Hims & Hers launched a semaglutide-based weight-loss pill priced at $129/month, 91% below Wegovy’s $1,400 list price.
- Novo Nordisk’s shares fell 6.3% on February 5, 2026, erasing $24 billion in market cap.
- Wegovy generated $5.7 billion in revenue in Q4 2025, representing 31% of Novo’s total sales.
- Analysts project Hims could capture 12–15% of the U.S. Wegovy market within six months.
- Hims & Hers shares rose 7.4% in after-hours trading following the announcement.
- Eli Lilly and Pfizer shares declined marginally, reflecting broader sector concerns about pricing pressure.
Novo Nordisk A/S (NVO) experienced a sharp sell-off in early trading on February 5, 2026, after Hims & Hers Health Inc. (HIMS) launched a semaglutide-based weight-loss medication under its own brand. The product, Hims Semaglutide 2.4 mg, is a biosimilar equivalent to Novo’s Wegovy, which has generated over $10 billion in annual revenue since its 2021 debut. The new offering is priced at $129 per month, roughly 91% lower than Wegovy’s list price of $1,400, signaling aggressive market disruption. The launch marks a pivotal moment in the obesity drug market, where high costs have limited patient access despite strong clinical results. Hims’ entry leverages its direct-to-consumer telehealth platform, enabling rapid patient onboarding and prescription fulfillment. Analysts estimate the new product could capture 12–15% of the U.S. Wegovy market within six months, primarily among uninsured or underinsured individuals. Novo Nordisk’s market capitalization dropped by $24 billion following the announcement, reflecting investor concerns over pricing pressure and erosion of premium positioning. The company reported Q4 2025 revenue of $18.3 billion, with Wegovy contributing $5.7 billion, or 31% of total sales. The Hims launch exposes Novo to increased competition, particularly as other generics are expected to enter the market by late 2026. The impact extends beyond Novo, affecting the broader pharmaceutical sector. Shares of Eli Lilly (LLY) and Pfizer (PFE), which also produce GLP-1 therapies, saw modest declines of 1.8% and 0.9%, respectively. Meanwhile, Hims & Hers gained 7.4% in after-hours trading, highlighting investor optimism around pricing strategy and market access.